GHRH Antagonist Peptide Shrinks Triple Negative Breast Cancer Tumors and Suppresses Inflammatory Signaling in Mice | Research

The takeaway

The GHRH antagonist peptide MIA-602 significantly reduced tumor growth and suppressed inflammatory cytokine expression in two models of triple negative breast cancer — a subtype with very limited treatment options.

7 inflammatory cytokines suppressed
MIA-602 silenced IFNγ, IL-1α, IL-4, IL-6, IL-8, IL-10, and TNFα — inflammatory signals that drive cancer resistance, spread, and immune evasion in triple negative breast cancer

What the researchers found

Treatment with the GHRH antagonist peptide MIA-602 significantly reduced tumor growth in mice bearing xenografts of two human TNBC cell lines (HCC1806 and MX-1).

Gene expression analysis revealed significant suppression of multiple inflammatory cytokines: IFNγ, IL-1α, IL-4, IL-6, IL-8, IL-10, and TNFα. These inflammatory cytokines are known to promote epithelial-mesenchymal transitions (EMT), drug resistance, and metastatic potential in breast cancer. siRNA silencing of GHRH receptors in vitro confirmed that the effects were receptor-mediated, inhibiting both GHRH-R genes and inflammatory cytokine expression.

Why it matters

Triple negative breast cancer is the most aggressive subtype and has the fewest treatment options — it doesn't respond to estrogen, progesterone, or HER2-targeted therapies. Finding that a peptide-based GHRH antagonist can both shrink these tumors and suppress the inflammatory signals that drive their resistance and spread opens a potential new treatment avenue for these patients.

How the study worked

In vivo studies used nude mice bearing xenografts of human TNBC cell lines HCC1806 and MX-1, treated with MIA-602. Tumor growth was measured. Quantitative gene expression analysis assessed inflammatory cytokine transcripts (IFNγ, IL-1α, IL-4, IL-6, IL-8, IL-10, TNFα). In vitro studies used siRNA-mediated GHRH receptor silencing to confirm receptor-dependent mechanisms in both cell lines.

What this study cannot tell us

This is a preclinical study using human tumor xenografts in immunocompromised nude mice, which does not fully replicate the human immune environment. The anti-tumor effects of MIA-602 in the context of a functional immune system are unknown. Clinical translation would require demonstration of efficacy and safety in human trials. The study focused on gene expression rather than protein-level cytokine measurements for most targets.

How to read the evidence

This is a preclinical study using two independent xenograft mouse models with confirmatory siRNA studies. While the dual-model approach and mechanistic validation provide strong preclinical evidence, no human studies have been conducted with MIA-602 for TNBC.

When this study was published

Published in 2012, this was an early study demonstrating the anti-inflammatory mechanisms of GHRH antagonists in cancer. Subsequent research has continued to develop these peptide analogs for various cancer applications.

The bigger picture

This study from Nobel laureate Andrew Schally's lab extends the role of GHRH peptide analogs from endocrine therapy to cancer immunology. By showing that GHRH antagonists suppress inflammatory cytokines in tumors, it connects peptide hormone biology to the tumor microenvironment — a link that could open new combination therapy strategies for treatment-resistant cancers.

Questions still open

Could GHRH antagonists be combined with immunotherapy or chemotherapy for enhanced effects in triple negative breast cancer?
Does MIA-602's suppression of inflammatory cytokines reduce metastatic potential in addition to primary tumor growth?
Would GHRH antagonists be effective in other treatment-resistant cancer subtypes that rely on inflammatory signaling?

Common questions

Why is triple negative breast cancer so hard to treat?

Triple negative breast cancer lacks three receptors (estrogen, progesterone, and HER2) that serve as targets for most breast cancer drugs. Without these targets, treatments like tamoxifen and Herceptin are ineffective. This leaves patients with primarily chemotherapy, which has significant side effects and limited long-term success. Finding new drug targets — like the GHRH receptor shown in this study — is critical for improving outcomes.

How could blocking GHRH receptors help fight cancer?

Cancer cells often hijack the body's growth signaling systems to fuel their own growth. Many cancers express GHRH receptors and use GHRH as an autocrine growth factor — essentially making their own growth signals. By blocking these receptors with antagonist peptides like MIA-602, the growth signal is cut off. This study also showed that blocking GHRH receptors suppresses inflammatory cytokines in tumors, which reduces the cancer's ability to spread, resist drugs, and evade the immune system.

Read the original research

Antagonists of growth hormone-releasing hormone suppress in vivo tumor growth and gene expression in triple negative breast cancers.

Oncotarget, 3(9), 988-97

View on PubMed ↗

Citation

Perez, Roberto; Schally, Andrew V; Vidaurre, Irving; Rincon, Ricardo; Block, Norman L; Rick, Ferenc G. (2012). Antagonists of growth hormone-releasing hormone suppress in vivo tumor growth and gene expression in triple negative breast cancers.. Oncotarget, 3(9), 988-97.